Published in Trends Mol Med on February 15, 2010
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell (2011) 3.31
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res (2012) 2.50
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Is HCMV a tumor promoter? Virus Res (2010) 1.81
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer (2015) 1.48
CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem (2012) 1.28
Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J Environ Res Public Health (2013) 1.26
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncol (2013) 1.22
Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene (2011) 1.19
Development of a unique small molecule modulator of CXCR4. PLoS One (2012) 1.18
Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol (2012) 1.17
Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer (2010) 1.17
The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci (2011) 1.15
CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep (2015) 1.14
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel) (2013) 1.10
Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget (2014) 1.08
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer (2011) 1.08
Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res (2012) 1.05
Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One (2014) 1.05
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol (2010) 1.04
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription. Am J Physiol Endocrinol Metab (2013) 1.02
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One (2011) 0.99
MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer (2014) 0.99
Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. Bioconjug Chem (2011) 0.99
The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. Cancer Microenviron (2011) 0.98
Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology (2014) 0.98
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis (2012) 0.97
In vitro cell migration and invasion assays. J Vis Exp (2014) 0.96
S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res (2013) 0.96
Delineating the core regulatory elements crucial for directed cell migration by examining folic-acid-mediated responses. J Cell Sci (2012) 0.96
EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS One (2014) 0.96
Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One (2011) 0.95
Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm (2014) 0.94
Ets1 blocks terminal differentiation of keratinocytes and induces expression of matrix metalloproteases and innate immune mediators. J Cell Sci (2010) 0.94
CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression. PLoS One (2012) 0.94
High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol (2012) 0.94
Open access microfluidic device for the study of cell migration during chemotaxis. Integr Biol (Camb) (2010) 0.93
Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol (2012) 0.93
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy (2011) 0.91
CXCL12 expression by healthy and malignant ovarian epithelial cells. BMC Cancer (2011) 0.91
Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm (2012) 0.91
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell (2014) 0.90
Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One (2013) 0.90
Chemokine network during adipogenesis in 3T3-L1 cells: Differential response between growth and proinflammatory factor in preadipocytes vs. adipocytes. Adipocyte (2014) 0.90
Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res (2015) 0.90
EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun (2015) 0.89
Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res (2013) 0.88
CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res (2013) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Epidermal p65/NF-κB signalling is essential for skin carcinogenesis. EMBO Mol Med (2014) 0.87
Regulation of the CCL2 gene in pancreatic β-cells by IL-1β and glucocorticoids: role of MKP-1. PLoS One (2012) 0.87
Expressions of CXCR7/ligands may be involved in oral carcinogenesis. J Mol Histol (2011) 0.87
CXCR2: a target for pancreatic cancer treatment? Expert Opin Ther Targets (2013) 0.87
The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients. BMC Cancer (2015) 0.86
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene (2015) 0.86
Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Exp Cell Res (2011) 0.86
Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors. ChemMedChem (2013) 0.85
Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed (2011) 0.85
CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. PLoS One (2014) 0.85
Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma. Medicine (Baltimore) (2015) 0.84
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res (2010) 0.84
Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. J Biol Chem (2017) 0.84
CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. Cancer Res (2015) 0.84
CXCR7 expression in esophageal cancer. J Transl Med (2013) 0.83
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
Increased serum levels of macrophage inflammatory protein-3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma. Medicine (Baltimore) (2014) 0.82
Novel process of intrathymic tumor-immune tolerance through CCR2-mediated recruitment of Sirpα+ dendritic cells: a murine model. PLoS One (2012) 0.82
Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med (2012) 0.82
Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3. Proc Natl Acad Sci U S A (2016) 0.81
Epigenetic silencing of CXCR4 promotes loss of cell adhesion in cervical cancer. Biomed Res Int (2014) 0.81
β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR. J Biol Chem (2013) 0.81
STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nat Commun (2015) 0.81
Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response. Comput Struct Biotechnol J (2013) 0.81
Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists. PLoS One (2013) 0.81
CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clin Exp Metastasis (2012) 0.81
Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget (2016) 0.81
Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med (2012) 0.80
Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol (2015) 0.80
Control of both myeloid cell infiltration and angiogenesis by CCR1 promotes liver cancer metastasis development in mice. Neoplasia (2013) 0.80
Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One (2014) 0.80
The hematopoietic chemokine CXCL12 promotes integration of human endothelial colony forming cell-derived cells into immature vessel networks. Stem Cells Dev (2014) 0.80
The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH. J Biol Chem (2015) 0.80
The Anti-inflammatory Effect of the CXCR4 Antagonist-N15P Peptide and Its Modulation on Inflammation-Associated Mediators in LPS-Induced PBMC. Inflammation (2015) 0.79
Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle (2014) 0.79
Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) (2012) 0.79
Monocyte chemotactic protein-1 promotes the proliferation and invasion of osteosarcoma cells and upregulates the expression of AKT. Mol Med Rep (2015) 0.79
Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: Clinicopathological correlations and significance. Oncol Lett (2012) 0.79
The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution. Elife (2015) 0.79
Control of CXCR2 activity through its ubiquitination on K327 residue. BMC Cell Biol (2014) 0.79
Cancer-related inflammation. Nature (2008) 34.21
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol (2006) 11.06
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 5.45
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73
Control of chemokine-guided cell migration by ligand sequestration. Cell (2008) 4.61
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res (2008) 3.97
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science (2008) 3.39
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
Cancer: Inflaming metastasis. Nature (2009) 3.09
T cell costimulation by chemokine receptors. Nat Immunol (2005) 3.00
The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol (2005) 2.98
Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol (2006) 2.92
Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev (2009) 2.85
Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell (2007) 2.48
HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell (2008) 2.46
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet (2007) 2.39
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
How chemokines invite leukocytes to dance. Nat Immunol (2008) 2.18
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity (2008) 2.13
Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell (2009) 2.10
Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res (2007) 2.02
Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res (2007) 1.95
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res (2009) 1.93
Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) (2009) 1.87
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem (2008) 1.71
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab (2009) 1.68
Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis (2007) 1.68
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer (2007) 1.62
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev (2007) 1.49
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol (2007) 1.49
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest (2007) 1.46
Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells (2008) 1.46
The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans (2006) 1.44
Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer (2009) 1.41
Chemokines as mediators of angiogenesis. Thromb Haemost (2007) 1.40
Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis (2007) 1.39
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut (2009) 1.36
CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J Clin Invest (2006) 1.36
Tumor angiogenesis: cause or consequence of cancer? Cancer Res (2007) 1.35
Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med (2008) 1.34
The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J (2006) 1.33
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst (2008) 1.29
Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene (2006) 1.24
The yin-yang of tumor-associated neutrophils. Cancer Cell (2009) 1.24
Retracted Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer (2008) 1.21
Chemokine blockers--therapeutics in the making? Trends Pharmacol Sci (2005) 1.21
Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ (2009) 1.07
Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res (2005) 1.06
Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat (2009) 1.06
First results for agents targeting cancer-related inflammation. J Natl Cancer Inst (2009) 1.02
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol (2008) 1.02
Natural post-translational modifications of chemokines. Biochem Soc Trans (2006) 0.96
Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett (2008) 0.95
Chemokine receptor antagonists: part 2. Expert Opin Ther Pat (2009) 0.90
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem (2006) 0.90
CCR9 homes metastatic melanoma cells to the small bowel. Clin Cancer Res (2008) 0.85
Promiscuous drugs as therapeutics for chemokine receptors. Expert Rev Mol Med (2009) 0.85
Chemokines and antagonists in non-Hodgkin's lymphoma. Expert Opin Ther Targets (2008) 0.82
Drug discovery targeting the chemokine system--where are we? Front Biosci (Elite Ed) (2009) 0.81
p53, chemokines, and squamous cell carcinoma. J Clin Invest (2007) 0.81
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res (2002) 2.19
Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13
Effects of flow and diffusion on chemotaxis studies in a microfabricated gradient generator. Lab Chip (2005) 2.11
The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol (2008) 2.08
A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem (2001) 1.94
Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol (2005) 1.80
Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. Mol Biol Cell (2004) 1.70
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55
BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res (2006) 1.54
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res (2004) 1.51
The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J Immunol (2006) 1.50
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41
Differential regulation of CXCR2 trafficking by Rab GTPases. Blood (2002) 1.38
Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. PLoS One (2010) 1.29
Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest (2010) 1.28
NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev (2010) 1.28
Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. J Biol Chem (2008) 1.25
Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. J Immunol (2005) 1.25
CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol (2008) 1.23
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci (2009) 1.13
Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw (2007) 1.13
Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res (2006) 1.12
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther (2004) 1.06
The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. J Biol Chem (2006) 1.05
Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. J Biol Chem (2001) 1.02
The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. J Biol Chem (2008) 1.00
Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol (2002) 1.00
PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry (2002) 0.99
Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res (2007) 0.98
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res (2009) 0.98
Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med (2007) 0.97
Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen (2003) 0.97
RhoB plays an essential role in CXCR2 sorting decisions. J Cell Sci (2007) 0.96
Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol (2003) 0.96
LIM and SH3 protein-1 modulates CXCR2-mediated cell migration. PLoS One (2010) 0.94
Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells. Biomed Microdevices (2008) 0.92
The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol (2012) 0.92
The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem (2008) 0.91
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell (2014) 0.90
The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res (2012) 0.88
IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse". PLoS One (2011) 0.87
Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol (2007) 0.87
Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1(CCMV). Virology (2007) 0.86
The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. J Cell Sci (2004) 0.86
INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res (2012) 0.85
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther (2009) 0.85
Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. FASEB J (2013) 0.84
Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. J Org Chem (2013) 0.84
Cell surface heparan sulfate participates in CXCL1-induced signaling. Biochemistry (2003) 0.83
CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res (2007) 0.83
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
Bimodal analysis reveals a general scaling law governing nondirected and chemotactic cell motility. Biophys J (2010) 0.81
Chemokine research moves on. Exp Cell Res (2011) 0.79
Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. J Leukoc Biol (2008) 0.79
Adaptor protein2 (AP2) orchestrates CXCR2-mediated cell migration. Traffic (2014) 0.78
Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. J Invest Dermatol (2015) 0.78
Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Toxicol Appl Pharmacol (2011) 0.78
The Meharry-Vanderbilt-Tennessee State University Cancer Partnership (MVTCP): History and Highlights of 20 Years of Accomplishments. J Health Care Poor Underserved (2022) 0.75
Micrometastatic Dormancy in Uveal Melanoma: A Comprehensive Review of the Evidence, Mechanisms, and Implications for Future Adjuvant Therapies. Int Ophthalmol Clin (2017) 0.75